1873. Rapid response to a Rhode Island college outbreak of meningococcal serogroup B disease: nation’s first widespread use of TrumenbaTM vaccine
Session: Poster Abstract Session: Vaccines: Meningococcal
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • posteridweek TF.png (158.0 kB)
  • Background: Two recombinant MenB vaccines are currently available for use during an outbreak: the 3-dose vaccine TrumenbaTM (rLP2086, Wyeth Pharmaceuticals, Inc.), and the 2-dose vaccine BexseroTM (4CMenB, Novartis Vaccines). In February 2015, an outbreak of meningococcal meningitis caused by Neisseria meningitidis serogroup B (MenB) was observed in students at college X (a Rhode Island college). All full-time undergraduate students at college X, graduate students under age 25 residing in dormitories, staff and graduate assistants under age 25, and residents on campus > 80 years and/or who were immunocompromised, were eligible for vaccination (n=3745). BexseroTM has been previously used in outbreaks of MenB on New Jersey and California college campuses. However, TrumenbaTM was more rapidly available at the time of this outbreak, thus it was a more suitable choice for this situation.  This outbreak provided a unique opportunity to assess adverse events following TrumenbaTM vaccination for the first time in a college setting.

    Methods: Vaccination coverage data was collected during the vaccination clinics in February and April. In collaboration with college X, the Rhode Island Department of Health (RI DOH), and the Centers for Disease Prevention and Control (CDC), strategies were reviewed and culture results were obtained. Informal question and answer sessions with university and DOH staff were conducted.

    Results: In February 2015, two culture-confirmed cases of N. meningitidis serogroup B (MenB) meningitis were observed, resulting in an attack rate of 44 per 100,000. This attack rate signified a 489-fold increase in MenB disease in 17-22 year olds in the United States, and thus represented an outbreak within the college’s community. Within 3 days of the identification of the second case, a rapid collaboration among the RI DOH, CDC, and college X allowed for the vaccination of 3061 students (and catch-up clinics later the same week vaccinated 464 students), preventing any further cases of N. meningitidis serogroup B infections to date. A coverage rate of 94% (n= 3525) was achieved.

    Conclusion: This outbreak marks the first time that Trumenba™ has been used as an intervention response to an outbreak, and allowed us a unique opportunity to monitor adverse events following vaccination with TrumenbaTM.

    Theresa Fiorito, MD, Pediatric Infectious Disease, Brown University/Hasbro Children´s Hospital, Providence, RI, Alysia Mihalakos, MPH, Center for Emergency Preparedness and Response, Rhode Island Department of Health, Providence, RI, Nicole Alexander-Scott, MD, MPH, Rhode Island Department of Health, Providence, RI and Penelope H. Dennehy, MD, FIDSA, FPIDS, Pediatrics, The Alpert Medical School of Brown University, Providence, RI

    Disclosures:

    T. Fiorito, None

    A. Mihalakos, None

    N. Alexander-Scott, None

    P. H. Dennehy, None

    << Previous Abstract | Next Abstract

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.